Profile young man standing arms out on hillside gazing out at sunrise over mountains.
ENROLLMENT STATUS: CLOSED!
The Vista clinical trial is no longer enrolling participants. While this trial has completed enrollment, other opportunities may be available to you or your child in the future.
Travel for Study-Related Assessments will be Provided for Eligible Study Participants and their Caregiver.
What is the Vista trial?
The Vista trial is studying an investigational (not yet approved for sale by government authorities like the FDA in the US or EMA in Europe) new gene therapy called laru-zova (also named AGTC-501) for patients with X-linked retinitis pigmentosa (XLRP).
The purpose of the Vista trial is to assess how well 2 different doses of laru-zova might work to preserve and/or improve vision and other symptoms of XLRP when compared to study participants who have not received laru-zova.
XLRP is an inherited rare genetic eye disease in which light-sensitive cells in the retina (the thin layer of tissue that lines the inner surface of the back of the eye) do not function correctly.
XLRP can be caused by a mutation in a gene called Retinitis Pigmentosa GTPase Regulator (RPGR).
A change in RPGR can result in loss of vision due to degeneration (breakdown) of special cells in the retina called photoreceptors, which are needed for vision.
